Right ventricular dysfunction and pulmonary hypertension following sub-massive pulmonary embolism

2016 ◽  
Vol 11 (6) ◽  
pp. 867-874 ◽  
Author(s):  
Chinthaka B. Samaranayake ◽  
Gordon Royle ◽  
Sharon Jackson ◽  
Elaine Yap
Keyword(s):  
Pulmonary Embolism ◽  
Pulmonary Hypertension ◽  
Right Ventricular ◽  
Ventricular Dysfunction ◽  
Right Ventricular Dysfunction ◽  
Massive Pulmonary Embolism

Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism

2006 ◽  
Vol 33 (2) ◽  
pp. 286-292 ◽  
Author(s):  
Damien Logeart ◽  
Lucien Lecuyer ◽  
Gabriel Thabut ◽  
Jean-Yves Tabet ◽  
Jean-Michel Tartière ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Right Ventricular ◽  
Ventricular Dysfunction ◽  
Right Ventricular Dysfunction ◽  
Massive Pulmonary Embolism

Clinical, historical and diagnostic findings associated with right ventricular dysfunction in patients with central and non-massive pulmonary embolism

2009 ◽  
Vol 5 (1) ◽  
pp. 53-59 ◽  
Author(s):  
Domenico Rendina ◽  
Silvana De Bonis ◽  
Giovanni Gallotta ◽  
Vincenzo Piedimonte ◽  
Giuseppe Mossetti ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Right Ventricular ◽  
Ventricular Dysfunction ◽  
Right Ventricular Dysfunction ◽  
Massive Pulmonary Embolism

Submassive and Massive Pulmonary Embolism: A Target for Thrombolytic Therapy?

1999 ◽  
Vol 82 (S 01) ◽  
pp. 104-108 ◽  
Author(s):  
Annette Geibel ◽  
Wolfgang Kasper ◽  
Stavros Konstantinides
Keyword(s):  
Pulmonary Embolism ◽  
Right Ventricular ◽  
Ventricular Dysfunction ◽  
High Risk Patient ◽  
Right Ventricular Dysfunction ◽  
Massive Pulmonary Embolism ◽  
Event Free Survival ◽  
Similar Extent ◽  
Free Survival ◽  
Fatal Bleeding

SummaryThrombolytic agents have been consistently demonstrated to dissolve pulmonary thrombi much more rapidly and effectively than heparin alone. Rapid resolution of pulmonary embolism (PE) is accompanied by a significant decrease in pulmonary artery pressure and an improvement in right ventricular function. However, it is no longer than 7 days until the findings of patients treated with heparin improve to a similar extent. Previous studies were not designed to determine whether this short-lasting difference in favor of thrombolysis can indeed affect the prognosis of patients with PE and thus justify the 1% (or even higher) risk of cerebral or fatal bleeding. Recently, two large registries demonstrated the importance of right ventricular dysfunction assessed by echocardiography as an independent predictor of mortality. Thrombolytic treatment was shown in one of these registries to be associated with a 50% reduction of death risk in clinically stable patients with right ventricular enlargement. It was thus possible to identify a group of patients with massive PE who are most likely to benefit from early thrombolysis. These findings now have to be confirmed by a prospective randomized trial which will compare thrombolysis with heparin alone in this high-risk patient population, focusing on clinical end points such as overall and event-free survival in the acute phase of PE.

Sign in / Sign up

Export Citation Format

Share Document